Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

and heart rate for Empatic are similar to or more favorable than the placebo-subtracted changes observed with Contrave, and there are no signals of cardiovascular concern in the Empatic development program, reassuring results of a cardiovascular outcomes trial with Contrave will be sufficient. In addition, while the FDA reiterated the belief that the teratogenicity potential for zonisamide is very concerning, the FDA will allow Phase 3 studies of Empatic to include women of childbearing potential who have a Body Mass Index that meets the FDA definition of overweight (>27kg/m2) in the presence of at least one weight-related comorbidity. Orexigen owns worldwide rights to Empatic. Prior to initiating Phase 3 studies of Empatic, the Company plans to seek a collaboration partner to help fund further clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the second quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 35366685. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Dec. 17, 2010 The Penn Transplant Institute, the ... Surgery at the Hospital of the University of Pennsylvania ... Program. The Program will operate under the leadership of ... Gift of Life Donor Program, the nonprofit organ and ...
... Dec. 17, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the company has established a ... and referral patterns and to provide strategic guidance on ... the company,s inception in 1990, Accuray has been focused ...
Cached Medicine Technology:Penn Medicine Establishes Hand Transplant Program 2Penn Medicine Establishes Hand Transplant Program 3Penn Medicine Establishes Hand Transplant Program 4Penn Medicine Establishes Hand Transplant Program 5Accuray Establishes Medical Affairs Function 2Accuray Establishes Medical Affairs Function 3
(Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
... First-ever Dr. Jacob Bolotin Awards to Be Presented ... The National Federation of,the Blind today launched the ... National Federation of the Blind will present cash ... contributions,toward achieving the full integration of the blind ...
... RARITAN, NJ, December 5 Jane Buckingham and ... Pill as part of The Modern,Girl,s Guide to the ... to the Pill, When: The Podcast will be ... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to the URL ...
... Dec. 5 HEI, Inc. (Nasdaq: HEII ),( ... Form 15 with the,Securities and Exchange Commission to voluntarily ... 1934. HEI expects that the,deregistration will be effective after ... application to deregister. As a result of this filing, ...
... the popularity of,fillers becoming mainstream, it,s no surprise ... facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic dermatologist ... such as Artefill, Radiesse and Sculptra contain injectable,plexiglass, ... all of,these products can cause foreign body reactions," ...
... Montreal and Boston have identified a potential new ... is a common side-effect of anti-retroviral medications to ... the HIV Metabolic Clinic at the McGill University ... at the Massachusetts General Hospital Program in Nutritional ...
... the Annals,of Emergency Medicine ("Increasing Rates of Emergency Department ... 2003") finds the rate of,elderly Americans seeking emergency care ... L. Noller, MD, President of the American College of,Obstetricians ... behalf of the Alliance of Specialty Medicine., "While ...
Cached Medicine News:Health News:National Federation of the Blind to Award $100,000 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Facial Deformity Danger? 2Health News:Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome 2Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2
... LH Ovulation Tests are qualitative immunoassays for detecting ... The procedure is fast and results are easy ... and is darker than the control band, then ... hours. If the test band does not ...
... been designed for women actively wishing to become ... identify the time of high fertility typically ... reaches her peak fertility. By doing so, it ... a number of test sticks and a hand ...
... Measurement System is indicated for the ... venous, or capillary whole blood of ... professional point-of-care setting. The microcuvettes ... use in the Hemopoint H2 Hemoglobin ...
... A dip-and-read urinalysis product available for ... systems. Clinitek® Microalbumin Strips provide albumin, ... one minute. The Clinitek® Microalbumin product ... in patients with diabetes or hypertension ...
Medicine Products: